patent.fyi
Applications  /  US 2026/0355220
United States Patent Application Publication

US 2026/0355220 A1

Published
Nov 12, 2026
Filed
Jul 17, 2026
Earliest date on the face
Feb 16, 2022
Classification
A61K 31/57
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Cyclodextrin solution reference

What ifWhat if the first comparison composition contains steroid dissolved in an aqueous cyclodextrin solution?
Claim language“suspended in polysorbate 80”

Hydroxypropyl beta-cyclodextrin forms soluble inclusion complexes with the steroid. The test introduces an aliquot containing a matched steroid mass and measures the amount that remains dissolved after dilution into the test medium.

1.2Water based suspension reference

What ifWhat if the second comparison composition suspends the steroid in water thickened with sodium carboxymethylcellulose?
Claim language“suspended in canola oil”

Hydrated sodium carboxymethylcellulose increases the viscosity of the aqueous vehicle and slows particle settling. The test mixes the suspension before transferring a measured aliquot into the dissolution vessel.

1.3Higher surfactant loading

What ifWhat if the third comparison composition contains surfactant at 2.0% of the mass of the treated crystalline steroid?
Claim language“no more than 0.5 wt %”

An aqueous solution supplies 2 mg of sodium lauryl sulfate per 100 mg of crystalline steroid during wet granulation. The dried granules disperse in the dissolution medium, where the surfactant promotes wetting of the crystals.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Oral formulation for veterinary pharmacokinetic studies

A veterinary research capsule contains treated 3α-OH-5β-pregnan-20-one dispersed in a lipophilic vehicle. The study protocol assigns capsule strengths to body mass bands for the study species. The protocol pairs the fraction released at 30 minutes in vitro with serial plasma measurements after oral administration.

Component substitution

Solid hydrocarbon matrix for oral capsules

Pharmaceutical-grade solid paraffin replaces the liquid lipophilic vehicle. Treated 3α-OH-5β-pregnan-20-one crystals and powdered mannitol are dispersed in molten paraffin, cooled, and milled into granules for capsule filling. In dissolution medium, mannitol dissolves from exposed granule surfaces and creates pores that expose embedded drug particles.

Parameter or scale variation

Early release across two medium volumes

A paddle apparatus tests capsules containing treated 3α-OH-5β-pregnan-20-one and a lipophilic vehicle in 500 mL and 900 mL of the same medium. Both runs use 37 °C and a paddle speed of 50 revolutions per minute. Filtered samples collected at 5, 10, 20, and 30 minutes provide cumulative release profiles for the two volumes. A mass balance corrects each result for drug removed in earlier samples.

Capsule blends with two granule sizes

Porous granules carrying treated 3α-OH-5β-pregnan-20-one and a lipophilic vehicle are sieved into 150–250 µm and 425–600 µm fractions. Each fraction is assayed for steroid content before blending. The two fractions contribute 25% and 75% of the steroid mass in one capsule blend, and 75% and 25% in a second blend. Dissolution testing compares the fraction released at 30 minutes at the same total steroid load.

Combination with existing systems

Capsule filling with recirculating suspension feed

A jacketed mixing vessel and a positive-displacement pump circulate a suspension of treated 3α-OH-5β-pregnan-20-one in a lipophilic vehicle. A short branch from the circulation loop supplies a liquid capsule filler, and excess suspension returns to the vessel. The filler meters the suspension into hard capsules, which pass to a band sealer. Fill mass and drug content are measured on samples taken at the beginning, middle, and end of the run.

Automated or data-driven variant

Automated calculation of relative release

An automated sampler draws aliquots through filters from dissolution vessels containing the test capsule and a selected reference suspension or crystalline formulation. A liquid chromatograph measures steroid concentration using a calibration curve generated from reference solutions. Software corrects for sampling withdrawals and divides the cumulative released mass by the starting steroid mass for each vessel. The software calculates relative release at 30 minutes by dividing the test fraction by the reference fraction, subtracting one, and multiplying by 100.

Specific version of a part

Matched polysorbate suspension test

The first comparison composition disperses the treated steroid in polysorbate 80 and supplies the same steroid mass as the oral dosage form. Identical paddle vessels provide the same medium, temperature and agitation, and the test divides the amount released by the dosage form at 30 minutes by the amount released by the comparison composition at that time. A ratio of 1.15 corresponds to 15% greater release.

Mixed canola oil suspension

Rotor-stator mixing disperses the treated steroid particles in refined canola oil. The test remixes the suspension before weighing the aliquot and measures dissolved steroid in a filtered sample taken 30 minutes after the aliquot enters the vessel.

Low surfactant crystalline granules

Wet granulation combines the treated crystalline steroid with mannitol, povidone and sodium lauryl sulfate at 0.4 mg per 100 mg of steroid. The test introduces the dried granules into the dissolution vessel and measures the dissolved steroid at 30 minutes.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0099776 A1
Published
Apr 22, 2010
Filed
Oct 20, 2009
Class
A61K 31/122
Document BUS 2013/0017183 A1
Published
Jan 17, 2013
Filed
Sep 14, 2012
Class
A61K 31/122
Claim 1
Document A
Document B
1.1at least one of 10%, 15%, 20%, and 25% greater than a 3α-OH-5β-pregnan-20-one 30-minute post in vitro test initiation release rate of a first comparison composition consisting essentially of treated 3α-OH-5β-pregnan-20-one suspended in polysorbate 80,
The oily suspension of atovaquone according to claim 1 wherein the surfactants are selected from the group consisting of sodium lauryl sulfate (SLS), polyoxyethylene sorbitan fatty acid esters, dialkyl sodium sulfosuccinates, polyglycolized glycerides; polyoxyethylene-polyoxypropylene block co-polymer; polyoxyethylene alkyl ethers, fatty acid esters of polyethylene glycol, and polyoxyethylene fatty acid esters or mixtures thereof.
A · US 2010/0099776 A1 · claim 3
For example, polysorbate 80 is a surfactant used to stabilize oil-in-water emulsions containing the non-polar active ingredients, for example, in nanometer-sized droplets suspended or dispersed in an aqueous phase or aqueous liquid, for example, aqueous medium, as spherical micelles, containing the hydrophilic portions of the molecule(s) facing the aqueous phase and the hydrophobic portions at the center of the spherical micelles, for example, surrounding the non-polar active
B · US 2013/0017183 A1 · ¶ 170
1.2at least one of 10%, 15%, 20%, and 25% greater than a 3α-OH-5β-pregnan-20-one 30-minute post in vitro test initiation release rate of a second comparison composition consisting essentially of treated 3α-OH-5β-pregnan-20-one suspended in canola oil, and
Vegetable oils include oils such as coconut oil, canola oil, cottonseed oil, olive oil, palm oil, corn oil, sesame oil, safflower oil, avocado oil and soybean oil.
A · US 2010/0099776 A1 · ¶ 26
1.3at least one of 10%, 15%, and 20% greater than a 3α-OH-5β-pregnan-20-one 30-minute post in vitro test initiation release rate of a third comparison composition comprising treated crystalline 3α-OH-5β-pregnan-20-one and a plurality of additives, said plurality of additives comprising a surfactant in an amount of no more than 0.5 wt % of said treated crystalline 3α-OH-5β-pregnan-20-one of said third comparison composition.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Atovaquone, a highly lipophilic compound resembling ubiquinone, has a low aqueous solubility, and that is the reason for the poor bioavailability of atovaquone after oral administration.
A · US 2010/0099776 A1 · ¶ 4
Atovaquone particles are reduced in size to facilitate absorption.
A · US 2010/0099776 A1 · ¶ 6
Provided are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals and supplements.
B · US 2013/0017183 A1 · ¶ 6
Because of poor water solubility, inclusion of non-polar compounds in products for human consumption, for example, supplements, foods and beverages, often is challenging.
B · US 2013/0017183 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355220 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355220/, SHA-256 314de9f5a5450af30521163adbc728bcebfeb1a76053c8b91db73138a8476d01
First published
Permanent addresshttps://patent.fyi/US20260355220/
Content fingerprint (SHA-256)314de9f5a5450af30521163adbc728bcebfeb1a76053c8b91db73138a8476d01
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi